Showing: 1 - 10 of 15 RESULTS

High Ten Environmental Issues Of The 21st Century

A penis rash can appear as a reddened area of the skin or as small, crimson bumps which may be accompanied by inflammation, itching and soreness. Cultural beliefs can impact the patients healthcare decisions. There have been claims that MacLaren Hall workers injured numerous kids, violently restrained children, and staff denied primary wants such as food and water. A win-win; healthy to your heart and good to your intestine.

By public health training, even simple issues comparable to carrying a flu masks in significantly affected areas, or knowing when to take vaccines for a selected sickness that is prominent at that time of the yr, always proves very efficient in limiting the number of individuals affected yearly.

A 2003 examine carried out within the US Department of Agriculture revealed that Diabetes kind II patients in Pakistan, who had an consumption of at the least a pinch of cinnamon of their daily weight loss plan, had their blood sugar levels significantly drop down.

There are several benefits to be derived from a robust core – a flat stomach, a powerful back, good posture, reduced pressure on the spine, effective transfer of energy to your legs and arms to raise, move or carry stuff round, greater psychological alertness, greater flexibility and an excellent heart.

Leading the questions with information about why you are asking and by sharing that different people have had comparable experiences makes this dialog more snug for the affected person. It is extremely essential that you simply ask your affected person every time if they’re in pain.…

Halfway house residents struggle to buy food, medicine after facility issues run of bad checks | Premium

Residents of a private halfway house in Colorado Springs say they struggled for weeks to access personal funds for food, medication and other necessities while their halfway house-issued checks were rejected by banks and check-cashing services.

The snag at Community Alternatives of El Paso persisted despite administrators’ promises to fix the problem and held up money that belongs to residents, who are required to hand over their paychecks and other income as a condition of their incarceration. The halfway house takes out money for rent and restitution and issues residents periodic allowances.

Remaining funds in the residents’ accounts are returned, minus any rent and restitution, after their release.  

Starting in late August, CAE’s bank, Community Banks of Colorado, repeatedly refused to honor the allowance checks, but not before some residents believed they had successfully deposited them.

The resulting confusion caused some residents to overdraw their personal checking accounts, deepening their financial woes as they prepared for release, several residents told The Gazette. Others were turned away from check-cashing services, forcing them to borrow money from family members and friends to cover their expenses.

Colorado Watch | Colorado halfway houses: Violence, sex and drugs as promised reforms lag

Although food is provided at CAE, many residents leave on work release and eat outside the facility, and others avoid the food that’s served, which comes from the El Paso County jail.

For Robert Thompson, the issue was the latest hurdle to obtaining a critical seizure medication while incarcerated at CAE.

After being transferred to CAE from the El Paso County jail in July, Thompson said he went two days without his daily medication. When administrators took him to an urgent care center after his repeated complaints, a provider there prescribed him half of his normal dose of 1,000 mg twice daily.

Thompson attributes his struggle over medications for contributing to seizures while in CAE custody that led to two trips by ambulance to UCHealth Memorial Hospital Central, where doctors restored his normal prescription and said his seizures could cause brain damage and even death.   

“They are endangering my life,” said Thompson, 59, who estimated that up to a third of the population — about 170 people as of August — struggled to access their money.

Thompson provided receipts from Walmart and King Soopers showing that his CAE checks were rejected by check-cashing services at a time he said he needed to refill his prescription. He eventually received a new check from CAE and purchased a refill two days before running out.

He said Walmart and King Soopers had so many problems with checks from CAE that they stopped accepting them.

In a memo posted Sept. 23 at CAE, and obtained by the newspaper, administrators instructed inmates not to cash checks issued between Aug. 20-Sept. 22, citing a “system error at the bank.”  

Two other residents said they had checks returned prior to that period, and receipts examined by the newspaper showed problems continued afterward.

Coronavirus outbreak at Colorado Springs halfway house widens,

KKR fret over Narine’s chucking complaint and Russell’s fitness issues : The Tribune India

Sharjah, October 11

Kolkata Knight Riders will have a lot on their plate when they take on a resurgent Royal Challengers Bangalore in an IPL match here on Monday with their lethal weapon Sunil Narine blunted by a chucking complaint and fitness clouds hovering over enforcer Andre Russell.

Narine, who have had multiple complaints of suspect action against him, is again in trouble after on-field umpires’ report post KKR’s thrilling two-run win against Kings XI Punjab in which the spinner played a massive role.

Not only KXIP, but the match against CSK also witnessed Narine’s entry after 10 overs, stifling Mahendra Singh Dhoni’s men. It seemed that the spinner was getting his mojo back and could have been a handful for Virat Kohli’s in-form men.

However, the first warning (a second one would bar him from bowling) from the IPL authorities is certain to ring alarm bells in the KKR camp as he was supposed to be Dinesh Karthik’s ‘go-to’ man in pressure situations.

It has been learnt that Narine has a problem with a few deliveries, especially the one that breaks back into a right-hander where there is believed to be an elbow flex beyond the permissible limit.

With his batting also not exactly clicking, how KKR fits him in the playing XI will be interesting, knowing that another offence could end his tournament as a bowler.

The two sides have won four of their six games with KKR ahead of RCB on net run rate but inconsistency in batting has been an issue for both the teams.

KKR is placed third in the standings and the two-time champions will be going all out for a victory at the Sharjah Cricket Stadium after registering two back-to-back wins against Chennai Super Kings and Kings XI Punjab.

Andre Russell, who hurt his knee when he accidentally dived into the advertisement boards after missing a catch on Saturday, could also be a doubtful starter.

Skipper Dinesh Karthik did not reveal the extent of the injury after the match against KXIP.

“Whenever Russell gets injured, you know it is hard. He is a very special player, he is a very special person. We need to go and look at him,” he said.

RCB, on the other hand, are coming into the game following a 37-run morale-boosting victory against CSK and will fancy their chances.

The biggest positive for RCB is that captain Kohli is slowly hitting the peak with the tournament reaching halfway stage. His unbeaten 90 off 52 balls against CSK with gold standard running between wickets will be remembered for years to come.

Young Devdutt Padikkal has been in good touch but AB de Villiers, who played some exquisite knocks at the beginning of the tournament, has looked off-colour in recent outings.


Kolkata Knight Riders: Dinesh Karthik (c/wk), Eoin Morgan, Shubman Gill, Tom Banton, Sunil Narine, Andre Russell, Nitish Rana, Rahul Tripathi, Kuldeep Yadav, Pat Cummins, Prasidh Krishna, Lockie Ferguson, Rinku Singh, Kamlesh Nagarkoti, Shivam Mavi, Nikhil Naik, Chris Green,

Ethicists say Trump special treatment raises fairness issues

The special treatment President Donald Trump received to access an experimental COVID-19 drug raises fairness issues that start with the flawed health care system many Americans endure and end with the public’s right to know more about his condition, ethics and medical experts say.

Regeneron Pharmaceuticals Inc. revealed on Tuesday how rare it was for anyone to get the drug it gave Trump outside of studies testing its safety and effectiveness. The drug, which supplies antibodies to help the immune system clear the coronavirus, is widely viewed as very promising.

Trump also received the antiviral remdesivir and the steroid dexamethasone, and it’s impossible to know whether any of these drugs did him any good.

“He deserves special treatment by virtue of his office,” said George Annas, who heads Boston University’s center for law and health ethics. “The question is whether it’s good treatment.”

These drugs are unproven for mild illness and have not been tested in combination. The steroid seems at odds with medical guidelines based on what doctors have said about the severity of his illness.

“The public is getting mixed messages about his condition and that’s a problem,” Annas said, adding that there’s a right to know anything that could affect Trump’s ability to do his job.


Trump’s doctors asked for the Regeneron drug under “compassionate use” rules, which allow a patient with a life-threatening disease to get an experimental medicine if they can’t enroll in a study testing it and there’s no good alternative.

Trump was given the drug at the White House on Friday before he was taken to Walter Reed National Military Medical Center. Walter Reed is not a site where the drug is being tested, so he may have met that criterion on technical grounds. Had he enrolled in a study, he would have risked being randomly assigned to a comparison group getting usual care rather than getting the drug.

Compassionate use requests are decided on a case-by-case basis, and both the drug company and the U.S. Food and Drug Administration must agree. An FDA spokeswoman refused comment on the FDA’s decision or to say how many others have asked for the drug.


Fewer than 10 of these requests have been granted, said Regeneron spokeswoman Alexandra Bowie. The drug is in limited supply, the priority is using it for the ongoing studies, and emergency access is granted “only in rare and exceptional circumstances,” she wrote in an email.

Regeneron also contacted Democratic presidential nominee Joe Biden’s campaign “to make them aware of the compassionate use mechanism, should they need to apply” if Biden becomes infected, Bowie wrote. “There was no promise of access to the medicine,” she added.

Alison Bateman-House, an ethicist at NYU Langone Health, said Regeneron’s overture to Biden raises concern.

“That crosses lines of appearing to promote a potentially unapproved product” in violation of FDA rules, she said. Rather than directing people to enroll in studies, it suggests “just call

FDA issues new vaccine guidance that pushes approval past election

The Food and Drug Administration has released its long-awaited guidance on how it will issue Emergency Use Authorizations (EUAs) for COVID-19 vaccines. The FDA says safety data on any vaccine will need to be monitored for at least two months after Phase 3 clinical trials are completed, likely closing the door on the possibility of approving a vaccine before Election Day.

“Data from Phase 3 studies should include a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adequate information to assess a vaccine’s benefit-risk profile,” the agency wrote in a briefing document for an upcoming vaccine advisory committee meeting. 

An EUA does not require as much proof as the more exhaustive, standard FDA approval process, but can expedite treatments deemed beneficial in an emergency.

The FDA’s Center for Biologics Evaluation and Research oversees the vaccine approval process and often consults with an outside advisory committee. The expert committee, set to meet on October 22, is made up of scientists, physicians, biostatisticians, and a consumer representative who are tasked with advising the FDA on the safety and efficacy of the vaccine. According to the FDA, the purpose of the meeting is not to “discuss any particular vaccine candidate.”

By providing the committee with two months of data on risks and benefits after the Phase 3 trial is completed, the panel of experts will have more time to screen for severe COVID-19 disease and adverse events among study participants, according to the guidance. 

FDA Commissioner Stephen Hahn said in a statement that he hoped the guidelines would help “the public understand our science-based decision-making process that assures vaccine quality, safety and efficacy.”

Time is essential in vaccine trials. Most adverse effects from a vaccine occur within the first month or two, but issues can also crop up long after they are administered, which is why companies continue to follow participants for at least two years, according to William Moss, executive director of Johns Hopkins’ International Vaccine Access Center. 

Approval of any EUA will require a “trade-off decision” between a vaccine’s societal value and “potential, rare, delayed side effects,” Moss told CBS News. 

President Trump has repeatedly asserted that a vaccine is imminent. On Labor Day, he said it could be ready “during the month of October.” On Monday, upon returning to the White House after a four-day stint in the hospital for his own coronavirus diagnosis, the president said that a vaccine is coming “momentarily.” 

“We have the best medicines in the world. And they all happened very shortly, and they’re all getting approved, and the vaccines are coming momentarily,” he said.

COVID-19, Trump and the race to a vaccine: Vo…


The FDA noted in its briefing document that the guidance is not legally enforceable. “Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited,” it said. 

The agency almost always follows the panel’s advice,

The Latest: Europol Issues Warning About Pandemic Cybercrime | World News

THE HAGUE, Netherlands — The European Union police agency says in a new report that cybercriminals are cashing in on the coronavirus crisis by targeting people and companies that are spending more time online due to work-from-home orders.

Europol issued its annual Internet Organised Crime Threat Assessment Monday. It underscores earlier warnings by the Hague-based police organization to the EU’s 27 member states about cybercrime during the pandemic.

The assessment covers all aspects of cybercrime. It cautions that “many individuals and businesses that may not have been as active online before the crisis became a lucrative target” for cybercriminals who are able to quickly adapt existing online crime to fit emerging vulnerabilities.

Criminals also used the global pandemic to spread disinformation about the virus for financial gain.

The report says that distributing fake news online about potential cures or treatments “facilitated criminals seeking to sell items that they claim will help prevent or cure COVID-19.”

Another element of cybercrime that has risen during the pandemic is the online distribution of images of the sexual abuse of children and livestreaming abuse. The report says that the COVID-19 crisis “revealed an extra surge in online distribution” of such material.


— Americans fault US govt over foreign powers for virus crisis

— Trump, moving to show strength, aims for Monday release

— Biden campaign says Democratic presidential nominee tested negative for virus

— EU top official self-isolating after contact with virus case

— Asian shares rise as investors are optimistic about Trump’s recovery from virus

Follow AP’s pandemic coverage at and


COPENHAGEN, Denmark — The Danish Health Authority has called off the traditional Halloween routine where costumed children and adults go from house to house, asking for trick or treats, and said that such practices “may be associated with the risk of spreading the infection.”

In its latest recommendation, the government agency suggests organizing Halloween parties only with people who see each other often and “replace the door-to-door candy collection with other activities, such as carving out pumpkins (or) an outdoor treasure hunt” or making Halloween paper decorations.

“If you serve sweets, make sure they are wrapped or portioned,” the agency said.

In the past years, the Oct. 31 festivities have become rather big in Denmark that has seen 30,057 cases and 659 deaths.

DETROIT — Buses returned to Detroit streets Monday after a three-day work stoppage by drivers over coronavirus protections and disputes with riders.

Police officers will increase their presence as part of a deal between the city and Amalgamated Transit Union Local 26. Riders must continue to wear masks and they must not cross a barrier or approach the driver.

Drivers “generally do not feel safe at work due to violent and threatening circumstances presented by customers and members of the public,” the memo states.

Detroit buses serve an average of 85,000 people a day.

A driver was suspended for 29 days for

Tough menopause may signal future heart issues, study says

As if the misery of hot flashes, night sweats and sleep troubles weren’t enough, now new research suggests that women who routinely experience moderate to severe menopausal symptoms have a higher risk of stroke and heart disease.

“This analysis assessed various menopausal symptoms and their association with health outcomes. Women with two or more moderate to severe menopausal symptoms had an increased risk of stroke and cardiovascular disease,” said study author Dr. Matthew Nudy, a cardiology fellow at Penn State Hershey Medical Center.

This study didn’t prove a cause-and-effect relationship, it only showed an association between menopausal symptoms and stroke and other heart and blood vessel diseases. It’s possible that menopause symptoms might not be a cause of these problems at all. It may be that other factors, such as obesity or diabetes, may lead to both menopausal symptoms and poor health outcomes.

Nudy also noted that past research has shown that women with menopausal symptoms often have other risk factors for heart disease and stroke, such as high blood pressure and cholesterol. They also may have poorer blood vessel health and increased levels of inflammation.

The latest research used data from a previous trial of more than 20,000 women between the ages of 50 and 79. The average follow-up time for the study was seven years.

The study looked for symptoms that included:

  • Hot flashes
  • Night sweats
  • Dizziness
  • Irregular heartbeats, such as a racing heartbeat or a feeling of skipped beats
  • Tremors
  • Feeling restless or fidgety
  • Feeling tired
  • Difficulty concentrating or forgetfulness
  • Mood swings
  • Vaginal dryness
  • Breast tenderness
  • Headache or migraine
  • Waking up multiple times at night.

The researchers found that when two or more of these symptoms were moderate to severe, the odds of stroke increased by 41%. The odds of any cardiovascular disease increased by 37% in women with two or more moderate to severe symptoms compared to women who had none.

Women who have multiple or more moderate to severe symptoms from menopause may be more likely to see a doctor for relief of those symptoms. Nudy said that’s a good opportunity for doctors to assess their heart disease and stroke risk.

Dr. Eugenia Gianos, director of women’s heart health at Lenox Hill Hospital in New York City, reviewed the study and said it reaffirms previous studies on potentially negative effects associated with menopausal symptoms.

“Many cardiac syndromes are unique to women and hormonal differences may explain the differences noted,” Gianos said.

“Unfortunately, supplementation with calcium and vitamin D did not improve outcomes,” she added.

Future research needs to determine what factors may be responsible for the negative effects of menopause and menopausal symptoms on women’s health, and find ways to ease menopausal symptoms and any poor outcomes linked to them, Gianos noted.

The findings were presented this week at the virtual meeting of the North American Menopause Society. Findings presented at meetings are typically viewed as preliminary until they’ve been published in a peer-reviewed journal.

More information

Learn more about menopausal symptoms from the U.S.

ACGME Issues Statement on the Executive Order on Race and Sex Stereotyping

ACGME Issues Statement on the Executive Order on Race and Sex Stereotyping

PR Newswire

CHICAGO, Sept. 30, 2020

CHICAGO, Sept. 30, 2020 /PRNewswire/ — The ACGME today issued a statement on the Presidential Executive Order on Combating Race and Sex Stereotyping. The Order, issued September 22, 2020 seemingly promotes training of employees to create an inclusive environment by avoiding race and sex stereotyping; however, that intent is subverted by defining divisive concepts in a way that turns mechanisms intended to protect into weapons of divisiveness and exclusion. The Executive Order is inconsistent with work done over the past 50 years to advance civil rights of minoritized and thereby marginalized communities in the United States and, through its mandates, risks further division and fostering a culture of enmity. This approach works against the ACGME’s mission to improve both health and health care for patients and communities and ultimately results in worsening health outcomes for those we are dedicated to serve.


The ACGME has sought to advance the work of diversity, equity, and inclusion and the elimination of health disparities through its programs, policies, and requirements. The goal of the ACGME is to foster a professional, equitable, respectful, and civil environment that is free from discrimination, sexual and other forms of harassment, mistreatment, abuse, or coercion of students, residents, and faculty and staff members, for the betterment of patient care through its accreditation processes.

Prohibiting institutions from providing certain types of education and training that the Executive Order deems to be promoting racial and sexual stereotypes would have devastating consequences on educating residents and fellows toward the goal of eliminating disparities in health outcomes and achieving equity within the health care profession. The Executive Order would similarly preclude residency and fellowship programs from developing curricula that reflect the needs of their communities, particularly in those of color and women, and promote inclusivity.

Read the full ACGME statement.

The ACGME is a private, non-profit, professional organization responsible for the accreditation of over 12,000 residency and fellowship programs and the approximately 865 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 145,000 resident and fellow physicians in 157 specialties and subspecialties. The ACGME’s mission is to improve health care and population health by assessing and advancing the quality of resident physicians’ education through accreditation.


View original content to download multimedia:

SOURCE Accreditation Council for Graduate Medical Education

Source Article

Ontario premier issues stern warning on second ‘wave or tsunami,’ Quebec enters red alert

COVID-19 In Canada
COVID-19 In Canada

Montreal, Quebec City and Chaudière-Appalaches move into the red alert level

Quebec Premier François Legault announced Monday that the regions of Montreal, Quebec City and Chaudière-Appalaches are moving into the red alert level, the most critical alert level in the province.

From Oct. 2 to Oct. 28, only people living at the same address can be inside a home at the same time, with an exception for a single caregiver.

Dining rooms in restaurants will be closed, but take-out services will be allowed, and other public spaces like bars, theatres, casinos and cinemas must shut down operations.

Places of worship can operate with a maximum of 25 people. Everyone must stay two metres apart outside and they must where a mask when that is not possible.

“We also need to reduce our contacts everywhere in Quebec,” Legault said. “We cannot wait for the red alert.”

“The number of cases is rising, if we don’t want our hospitals to be submerged, if we want to limit the number of deaths we must act strongly right now.”

Ontario could see thousands of COVID-19 cases a day in second wave

Dr. David Williams, Ontario’s chief medical officer of health, explained that there are two models for the future of the province’s second wave, one that would lead to thousands of new cases a day.

The “most concerning” model is the “penultimate or the tsunami-type wave” where there is rapid exponential growth in cases that impacts the whole province.

“We would be up and having anywhere from three to four to five thousand new cases a day,” Dr. Williams said at a press conference on Monday.

The second model is identified by “undulating waves” and would continue into 2021, but modellers have not identified how big each of these shorter waves would be.

“This is a wakeup call for us, we have to pay attention to this in a serious way,” the Ontario’s chief medical officer of health said.

Dr. Williams added that considerations are still being brought forward to the public health measures table related to moving all of Ontario, or certain areas of the province, back to Stage 2 of Ontario’s reopening plan. He added that the core difference between the COVID-19 situation now and when restrictions were initially put in is that virus was all over the province, instead of mainly being identified in more urban areas of Ontario. Dr. Williams confirmed that some of the recommendations being put forward are “pan-Ontario” measures and restrictions.

The province’s chief medical officer of health asked the public to be cautious about who they interact with, particularly individuals who are not taking the COVID-19 pandemic seriously.

“We’re getting some people out there who are basically saying, we don’t really care about the rules and we’re going to be cavalier about it,” Dr. Williams explained. “I would avoid contact with those people…because you have no idea, and they have no idea, if they’ve been exposed or not at this stage.”

CytRx Issues Statement Regarding Orphazyme’s Global Offering

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) (“Orphazyme”) on the September 29, 2020 pricing of its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe. According to Orphazyme, the aggregate gross proceeds from its global offering will amount to approximately DKK 534,534,637 ($83,777,606 using a DKK/USD exchange rate of 6.3804) (assuming no exercise of the option to purchase additional shares) and DKK 614,714,770 ($96,344,237 using a DKK/USD exchange rate of 6.3804) (assuming full exercise of the option to purchase additional shares). CytRx has an agreement with Orphazyme that can yield milestone payments and royalties based on potential future sales of arimoclomol.

In connection with Orphazyme’s global offering, it disclosed receipt of a filing communication from the U.S. Food and Drug Administration (“FDA”) relating to the agency’s ordinary course review of its new drug application (“NDA”) for arimoclomol in the treatment of Niemann-Pick disease Type C (“NPC”). The filing communication follows acceptance on a Priority Review basis by the FDA of Orphazyme’s NDA for arimoclomol in NPC and the agency’s establishment of the Prescription Drug User Fee Act (“PDUFA”) target action date of March 17, 2021. Orphazyme stated that its receipt of the filing communication does not impact the FDA’s acceptance of its NDA, the target PDUFA action date or the Priority Review determination. Orphazyme’s disclosure notes that the filing communication constitutes preliminary notice from the FDA of potential review issues as part of its ordinary course review of the NDA and is not necessarily indicative of deficiencies that may be identified during the review. Orphazyme has stated that it intends to discuss the filing communication with the FDA.

In accordance with applicable securities laws, Orphazyme amended the registration statement on Form F-1 on file with the U.S. Securities and Exchange Commission. For further information concerning the FDA filing communication, we refer you to the “Recent Developments” section on Page 6 of Orphazyme’s amended Form F-1 filed on September 28, 2020.

CytRx will continue to provide updates that are relevant to its agreement with Orphazyme.

About CytRx Corporation

CytRx Corporation (OTCQB:CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in four indications including amyotrophic lateral sclerosis (“ALS”), Niemann-Pick disease Type C (“NPC”), Gaucher disease and sporadic Inclusion Body Myositis (“sIBM”). Learn more at

About Orphazyme

Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life threatening or debilitating rare diseases. Their research focuses on developing therapies for diseases caused by misfolding of proteins including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four